<DOC>
	<DOCNO>NCT02271165</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety human immunoglobulin SCIg form Hizentra ( Immune globulin Subcutaneous ) patient Dermatomyositis . Hizentra provide effective protection infection maintain steady normal level immunoglobulin body ) patient primary immunodeficiency . At present , patient steroid resistant dermatomyositis treat IVIg ( The healthy antibody IVIG block damage antibody attack muscle skin dermatomyositis ) treatment . An evaluation make see SCIg suitable replacement exerts immunomodulatory effect complement antibody .</brief_summary>
	<brief_title>Subcutaneous Immunoglobulin ( Hizentra ) Patients With Dermatomyositis : A Proof Concept Study</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Men woman age &gt; 18 year 2 . Diagnosis DM base standard criterion 3 . Receiving equivalent least 0.4 g/kg IVIg every 4 week ( IVIg group ) 4 . Established response IVIg dependence IVIg maintain status establish either symptomatic worsening condition end interdose interval group worsen reduction dose within previous 12 month ( IVIg group ) 5 . IVIg regimen stable 12 week IVIg ( minor change permit provide dose change 15 % less ) ( IVIg group ) 6 . Stable dose steroid and/or immunosuppressives 12 week change schedule intend . 1 . Pregnancy , plan pregnancy , breast feeding unwillingness practice contraception 2 . Severe concurrent medical condition would prevent treatment assessment , include significant hematological , renal liver dysfunction malignancy 3 . Initiation immunomodulatory treatment IVIg past 24 week modification immunomodulatory treatment IVIg past 12 week . 4 . Participation trial investigational medicinal product past 12 week 5 . Presence skin infection unrelated dermatomyositis , severe skin involvement Presence medical condition , opinion investigator might interfere performance interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>